Evidence map›Paper›PMID 27297952›Full record

ArticleAIDS care2016

Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC.

Amanda D Castel, Mariah M Kalmin, Rachel L D Hart, Heather A Young, Harlen Hays, Debra Benator, Princy Kumar, Richard Elion, David Parenti, Maria Elena Ruiz and 16 more

Registry-linked trialAbstract read
In one paragraph

Article in AIDS care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04998019 (Pragmatic Efficacy Trial of mHealth to Improve HIV Outcomes in the DC Cohort), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04998019 nacompletednot on this mapstarted 2022, after this paper: background citation

Pragmatic Efficacy Trial of mHealth to Improve HIV Outcomes in the DC Cohort

TypeinterventionalSponsorGeorge Washington UniversityRan2022 to 2025Enrolled682ConditionsHIV/AIDSArmsPositiveLinks
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Amanda D Castela Department of Epidemiology and Biostatistics , George Washington University Milken Institute School of Public Health , Washington , DC , USA.
Mariah M Kalmina Department of Epidemiology and Biostatistics , George Washington University Milken Institute School of Public Health , Washington , DC , USA.
Rachel L D Hartb Cerner Corporation , Kansas City , MO , USA.
Heather A Younga Department of Epidemiology and Biostatistics , George Washington University Milken Institute School of Public Health , Washington , DC , USA.
Harlen Haysb Cerner Corporation , Kansas City , MO , USA.
Debra Benatorc Veterans Affairs Medical Center , Washington , DC , USA.
Princy Kumard Division of Infectious Diseases, Georgetown University , Washington , DC , USA.
Richard Elione Whitman-Walker Health , Washington , DC , USA.
David Parentif Division of Infectious Disease , George Washington Medical Faculty Associates , Washington , DC , USA.
Maria Elena Ruizg Division of Infectious Diseases, Department of Medicine , Washington Hospital Center , Washington , DC , USA.
Angela Woodh Family and Medical Counseling Service , Washington , DC , USA.
Lawrence D'Angeloi Burgess Adolescent Clinic, Children's National Medical Center , Washington , DC , USA.
Natella Rakhmaninaj Special Immunology Service Pediatric Clinic Children's National Medical Center , Washington , DC , USA.
Sohail Ranak Department of Pediatric and Child Health , Howard University Hospital , Washington , DC , USA.
Maya Bryantl Howard University Hospital Adult Infectious Disease Clinic , Washington , DC , USA.
Annick Heboum MetroHealth , Washington , DC , USA.
Ricardo Fernándezn La Clinica Del Pueblo , Washington , DC , USA.
Stephen Abbotto Unity Health Care , Washington , DC , USA.
James Petersona Department of Epidemiology and Biostatistics , George Washington University Milken Institute School of Public Health , Washington , DC , USA.
Kathy Woodp Cerner Corporation , Vienna , VA , USA.
Thilakavathy Subramanianb Cerner Corporation , Kansas City , MO , USA.
Jeffrey Binkleyq Cerner Corporation , Culver City , CA , USA.
Lindsey Powers Happa Department of Epidemiology and Biostatistics , George Washington University Milken Institute School of Public Health , Washington , DC , USA.
Michael Kharfenr District of Columbia Department of Health , HIV/AIDS, Hepatitis, Sexually Transmitted Diseases, Tuberculosis Administration (HAHSTA) , Washington , DC , USA.
Henry Masurs Department of Critical Care Medicine , National Institutes of Health , Bethesda , MD , USA.
Alan E Greenberga Department of Epidemiology and Biostatistics , George Washington University Milken Institute School of Public Health , Washington , DC , USA.

Funding

CPCRA Clinical Trials UnitU01AI069503 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI GORDIN, FRED M · 2007 to 2011
$33.9M
DC Partnership for HIV/AIDS Progress (DC PFAP)ZIACL009010 · CLC · CLINICAL CENTER · PI MASUR, HENRY · 2010 to 2025
$0k
NIAID NIH HHS U01 AI069503
6 · The paper itself

Abstract

One goal of the HIV care continuum is achieving viral suppression (VS), yet disparities in suppression exist among subpopulations of HIV-infected persons. We sought to identify disparities in both the ability to achieve and sustain VS among an urban cohort of HIV-infected persons in care. Data from HIV-infected persons enrolled at the 13 DC Cohort study clinical sites between January 2011 and June 2014 were analyzed. Univariate and multivariate logistic regression were conducted to identify factors associated with achieving VS (viral load < 200 copies/ml) at least once, and Kaplan-Meier (KM) curves and Cox proportional hazards models were used to identify factors associated with sustaining VS and time to virologic failure (VL ≥ 200 copies/ml after achievement of VS). Among the 4311 participants, 95.4% were either virally suppressed at study enrollment or able to achieve VS during the follow-up period. In multivariate analyses, achieving VS was significantly associated with age (aOR: 1.04; 95%CI: 1.03-1.06 per five-year increase) and having a higher CD4 (aOR: 1.05, 95% CI 1.04-1.06 per 100 cells/mm(3)). Patients infected through perinatal transmission were less likely to achieve VS compared to MSM patients (aOR: 0.63, 95% CI 0.51-0.79). Once achieved, most participants (74.4%) sustained VS during follow-up. Blacks and perinatally infected persons were less likely to have sustained VS in KM survival analysis (log rank chi-square p ≤ .001 for both) compared to other races and risk groups. Earlier time to failure was observed among females, Blacks, publically insured, perinatally infected, those with longer standing HIV infection, and those with diagnoses of mental health issues or depression. Among this HIV-infected cohort, most people achieved and maintained VS; however, disparities exist with regard to patient age, race, HIV transmission risk, and co-morbid conditions. Identifying populations with disparate outcomes allows for appropriate targeting of resources to improve outcomes along the care continuum.

Indexed as

Health Status DisparitiesInfectious Disease Transmission, VerticalSustained Virologic ResponseAdultAge FactorsCD4 Lymphocyte CountCohort StudiesDistrict of ColumbiaFemaleHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedRacial GroupsSex Factorscare continuumcohortdisparitiesHIVViral suppression

Identifiers

PMID27297952
PMCPMC5084086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.